NOTCH signaling is activated in and contributes to resistance in enzalutamide-resistant prostate cancer cells.

ABSTRACT: Prostate cancer is the second leading cause of cancer death among men in the United States. The androgen receptor (AR) antagonist enzalutamide is a Food and Drug Administration-approved drug for treatment of patients with late-stage prostate cancer and is currently under clinical study for early-stage prostate cancer treatment. After a short positive response period, tumors will develop drug resistance. In this study using RNA-Seq and bioinformatics analyses, we observed that NOTCH signaling is a deregulated pathway in enzalutamide-resistant cells. NOTCH2 and c-MYC gene expression positively correlated with AR expression in samples from patient with hormone refractory disease in which AR expression levels correspond to those typically observed in enzalutamide resistanc

SUBMITTER: Farah E 

PROVIDER: S-EPMC6544854 | biostudies-literature | 2019 May

REPOSITORIES: biostudies-literature